Hyperprolactinemia and erectile dysfunction

Czech version

Authors: Marek Broul ^1-3; Aneta Hujová ³; Lucie Radovnická ⁴; Alberto Malucelli ⁵; Eva Jozífková ⁶
Authors‘ workplace: Sexuologické oddělení, Krajská zdravotní, a. s. – Masarykova nemocnice v Ústí nad Labem, o. z. ¹; Urologické oddělení, Krajská zdravotní, a. s. – Nemocnice Litoměřice, o. z. ²; Katedra ošetřovatelství, Fakulta zdravotnických studií UJEP v Ústí nad Labem ³; Interní oddělení, Krajská zdravotní, a. s. – Masarykova nemocnice v Ústí nad Labem, o. z. ⁴; Neurochirurgická klinika FZS UJEP a Krajská zdravotní, a. s. – Masarykova nemocnice v Ústí nad Labem, o. z. ⁵; Katedra biologie, Přírodovědecká fakulta UJEP v Ústí nad Labem ⁶
Published in: Ces Urol 2025; 29(1): 17-21
Category: Original article
doi: https://doi.org/10.48095/cccu2025003

Overview

In addition to hypogonadism, other endocrine diseases are associated with male sexual dysfunction. In this article, we review the role of the pituitary hormone prolactin in male sexual dysfunction, and in particular in erectile dysfunction. Erectile dysfunction is common in men with hyperprolactinemia. Treatment of this primary cause may affect normal erectile function. In our patient cohort, after treatment of hyperprolactinemia (medical and surgical), prolactin levels normalized in all treated patients. Erectile dysfunction in all men was treated with some type of phosphodiesterase 5 inhibitor – i.e. sildenafil, tadalafil, vardenafil, avanafil. After the treatment of the primary cause of erectile dysfunction, there was then also an improvement in IIEF-5 (International Index of Erectile Function) score and therefore erectile function in all our patients.

Keywords:

erectile dysfunction, prolactin, pituitary adenoma, IIEF-5 questionnaire, hyperprolactine-mia

Sources

1. Miller JB, Howards SS, Mcleod RM. Serum prolactin in organic and psychogenic impotence. J Urol 1980; 123(6): 862– 864. doi: 10.1016/ s0022-5347(17)56166-2.

2. Perryman RL, Thorner MO. The effects of hyperprolactinemia on sexual and reproductive function in men. J Androl 1981; 5: 233– 242.

3. Zeitlin SI, Rajfer J. Hyperprolactinemia and erectile dysfunction. Rev Urol 2000; 2(1): 39– 42.

4. Riddle O, Bates RW, Dykshorn SW. The preparation, identification and assay of prolactin – a hormone of the anterior pituitary. Am J Physiol – Legacy Content 1933: 191– 216. doi: 10.1152/ ajplegacy.1933.105.1.191.

5. Kelly MA, Rubinstein M, Asa SL et al. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 1997; 19(1): 103– 113. doi: 10.1016/ s0896-6273(00)80351-7.

6. Al-Chalabi M, Bass AN, Alsalman I. Physiology, Prolactin. In: StatPearls. Treasure Island (FL): StatPearls Publishing 2025 [online]. Available from: http:/ / www.ncbi.nlm.nih.gov/ books/ NBK507829/ .

7. Ježková J, Brutvan T. Adenomy hypofýzy z pohledu internisty. Vnitr Lek 2024; 70(1): 7– 12. doi: 10.36290/ vnl.2024.001.

8. Kršek M. Hyperprolaktinémie a prolaktinomy. Interní Med 2002; 4(11): 530-536.

9. Faglia G. Prolactinomas and hyperprolactinemic syndrome. In: DeGroot LJ, Jameson JL (eds.) Endocrinology (4th ed). Philadelphia: Saunders 2000: 329– 342.

10. Johnson 3rd AR, Jarow JP. Is routine endocrine testing of impotent men necessary? J Urol 1992; 147(6): 1542– 1543. doi: 10.1016/ s0022-5347(17)
37620-6.

11. Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158(5): 1764– 1767. doi: 10.1016/ s0022-5347(01)64123-5.

12. Slag MF, Morley JE, Elson MK et al. Impotence in medical clinic outpatients. Jama 1983; 249(13): 1736– 1740.

13. Broul M, Kučerová P, Jozífková E et al. Treatment of thyroid disorder supported by 5-phosphodiesterase inhibitors improved erectile dysfunction in patients with hypo-and hyperthyroidism. Neuro Endocrinol Lett 2024; 45(3): 180– 187.

14. Carter JN, Tyson JE, Tolis G et al. Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med 1978; 299(16): 847– 852. doi: 10.1056/ NEJM197810192991602.

15. Tolis G. Prolactin: physiology and pathology. Hosp Pract 1980; 15(2): 85– 95. doi: 10.1080/ 21548331.1980.11946556.

16. Veselský Z. Vztah prolaktinu a testosteronu u mužů se sexuální dysfunkcí. Urolog. pro Praxi 2005; 6: 264– 268.

17. Dombrowski RC, Romeo JH, Aron DC. Verapamil-induced hyperprolactememia complicated by a pituitary incidentaloma. Ann Pharmacother 1995; 29(10): 999– 1001. doi: 10.1177/ 106002809502901009.

18. Nickel JC, Morales A, Condra M et al. Endocrine dysfunction in impotence: incidence, significance and cost-effective screening. J Urol 1984; 132(1): 40– 43. doi: 10.1016/ s0022-5347(17)49454-7.

19. Zeitlin SI, Rajfer J. Hyperprolactinemia and erectile dysfunction. Rev Urol 2000; 2(1): 39– 42.

20. Buvat, J. Hyperprolactinemia and sexual function in men: a short review. Int J Impot Res 2003; 15(5): 373– 377. doi: 10.1038/ sj.ijir.3901043.